Regulatory T Cells Boost Efficacy of Post-Infarction Pluripotent Stem Cell-Derived Cardiovascular Progenitor Cell Transplants
Authors:
- Aline Derisio de LimaAline Derisio de Lima
- Hernán Gonzalez-King GaribottiHernán Gonzalez-King Garibotti
- Qing-Dong WangQWQing-Dong Wang
- Cecilia GraneliCGCecilia Graneli
- Tania IncittiTITania Incitti
- Valérie BellamyVBValérie Bellamy
- Maria Eduarda Anastácio Borges CorrêaMCMaria Eduarda Anastácio Borges Corrêa
- Myriam AssalMAMyriam Assal
- Makoto MiyaraMMMakoto Miyara
- Jean-Sébastien SilvestreJSJean-Sébastien Silvestre
- Karin JennbackenKJKarin Jennbacken
- Philippe MenaschéPMPhilippe Menasché
Open Access
Abstract
Cell therapy is promising for heart failure treatment, with growing interest in cardiovascular progenitor cells (CPCs) from pluripotent stem cells. A major challenge is managing the immune response, due to their allogeneic source. Regulatory T cells (Treg) offer an alternative to pharmacological immunosuppression by inducing immune tolerance. This study assesses whether Treg therapy can mitigate the xeno-immune response, improving cardiac outcomes in a mouse model of human CPC intramyocardial transplantation. CPCs stimulated immune responses in allogeneic and xenogeneic settings, causing proliferation in T cell subsets. Tregs showed immunosuppressive effects on T lymphocyte populations when co-cultured with CPCs. Post infarction, CPCs were transplanted intramyocardially into an immune-competent mouse model 3 weeks after myocardial infarction. Human or murine Tregs were intravenously administered on transplantation day and three days later. Control groups received CPCs without Tregs or saline (PBS). CPCs with Tregs improved LV systolic function in three weeks, linked to reduced myocardial fibrosis and enhanced angiogenesis. This was accompanied by decreased splenocyte NK cell populations and pro-inflammatory cytokine levels in cardiac tissue. Treg therapy with CPC transplantation enhances cardiac functional and structural outcomes in mice. Though it does not directly avert graft rejection, it primarily affects NKG2D+ cytotoxic cells, indicating systemic immune modulation and remote heart repair benefits.Keywords
Funding Information
- AstraZeneca (ANR-10-LABX-0073)
- Labex REVIVE (ANR-10-LABX-0073)
This publication has 31 references indexed in Scilit:
- Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primateCell Stem Cell, 2024
- The Role of Regulatory T Cells in Heart Repair After Myocardial InfarctionJournal of Cardiovascular Translational Research, 2023
- Current status and perspectives of regulatory T cell-based therapyJournal of Genetics and Genomics, 2022
- The cardiosplenic axis: the prognostic role of the spleen in heart failureHeart Failure Reviews, 2022
- Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelinesPharmacology & Therapeutics, 2022
- A Phenotypic Screening Approach Using Human Treg Cells Identified Regulators of Forkhead Box p3 ExpressionACS Chemical Biology, 2019
- Human ISL1+ Ventricular Progenitors Self-Assemble into an In Vivo Functional Heart Patch and Preserve Cardiac Function Post InfarctionMolecular Therapy, 2018
- Transplantation of Human Embryonic Stem Cell–Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular DysfunctionJACC, 2018
- Cardiomyocytes Derived from MHC-Homozygous Induced Pluripotent Stem Cells Exhibit Reduced Allogeneic Immunogenicity in MHC-Matched Non-human PrimatesStem Cell Reports, 2016
- The Th17/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fractionClinica Chimica Acta, 2010